Cancer diagnostics company NeoGenomics Inc (NASDAQ:NEO) confirmed on Monday that it has completed its acquisition of Pathline LLC, a laboratory in New Jersey.
This acquisition enhances NeoGenomics' commercial presence in the Northeast United States and expands access to its oncology testing services in the Tri-state area.
Pathline is CLIA, CAP and NYS certified, aligning with NeoGenomics' standards for high-quality diagnostic testing.
Through this transaction NeoGenomics broadens access to its comprehensive oncology test menu, expands its service capabilities and accelerates growth in molecular and haematology-oncology diagnostics.
IDEAYA Biosciences advances Phase 3 design for darovasertib in primary uveal melanoma
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Sichuan Kelun-Biotech reveals sacituzumab tirumotecan (sac-TMT) clinical studies results
Amgen's IMDELLTRA shows superior overall survival in small cell lung cancer trial
EDX Medical launches new testicular cancer detection test in UK
Oncolytics Biotech signs share purchase agreement with Alumni Capital
SciTech Development secures second FDA clearance for ST-001 in early-stage cancer trials
MaaT Pharma receives positive DSMB safety recommendation for Phase 2b trial of MaaT033